Patents by Inventor Katia Beider

Katia Beider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy
    Patent number: 8765683
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.
    Type: Grant
    Filed: January 29, 2012
    Date of Patent: July 1, 2014
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
    Patent number: 8663651
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.
    Type: Grant
    Filed: December 23, 2007
    Date of Patent: March 4, 2014
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • METHODS FOR OBTAINING A THERAPEUTICALLY EFFECTIVE AMOUNT OF HEMATOPOIETIC PRECURSOR CELLS AND LONG TERM ENGRAFTMENT THEREOF
    Publication number: 20140030211
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Application
    Filed: May 8, 2013
    Publication date: January 30, 2014
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Amnon PELED, Michal Begin, Katia Beider, Michal Abraham
  • Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
    Patent number: 8455450
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Grant
    Filed: December 23, 2007
    Date of Patent: June 4, 2013
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY
    Publication number: 20120207748
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.
    Type: Application
    Filed: January 29, 2012
    Publication date: August 16, 2012
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • CCL20-SPECIFIC ANTIBODIES FOR CANCER THERAPY
    Publication number: 20110123542
    Abstract: The invention is directed to the field of cancer therapy, specifically to the use of anti-CCL20 antibodies for the treatment of neoplastic disorders. The invention provides compositions and methods useful for the treatment of CCR6 and CX-CR4 expressing tumors.
    Type: Application
    Filed: June 24, 2009
    Publication date: May 26, 2011
    Inventors: Amnon Peled, Katia Beider
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY
    Publication number: 20100184694
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.
    Type: Application
    Filed: December 23, 2007
    Publication date: July 22, 2010
    Applicant: BIOKINE THERAPEUTICS LTD.
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY
    Publication number: 20100166715
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
    Type: Application
    Filed: December 23, 2007
    Publication date: July 1, 2010
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
  • T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION
    Publication number: 20100143334
    Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.
    Type: Application
    Filed: December 23, 2007
    Publication date: June 10, 2010
    Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham